- Home
- TCBP
as 01-17-2025 4:00pm EST
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
| Founded: | 2013 | Country: | United Kingdom |
| Employees: | N/A | City: | HOLYTOWN |
| Market Cap: | 5.0M | IPO Year: | 2022 |
| Target Price: | $2.40 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -78.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.37 - $32.70 | Next Earning Date: | 11-25-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TC BioPharm (Holdings) plc News
TCBP Breaking Stock News: Dive into TCBP Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
TCBP Announces H5N1 Proof of Concept Studies Intention
PR Newswire
6 days ago
TCBP to Present at Sequire Investor Summit 2025
PR Newswire
12 days ago
/C O R R E C T I O N -- TC BioPharm/
PR Newswire
12 days ago
TCBP Trading Continues Unabated on Nasdaq Stock Exchange
MT Newswires
18 days ago
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires
18 days ago
Sector Update: Health Care
MT Newswires
18 days ago
TC BioPharm Shares Rise as Talks With Acquisition Targets Advance
PR Newswire
19 days ago
TCBP Provides Update on Acquisition Strategy and Current Targets
Compare TCBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCBP TC BioPharm (Holdings) plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.